Table 6.
Ratio of median prices between the bioequivalents and the referent in 2011 and 2016 shown as percentage (the difference between 2011 and 2016 is also shown)
| Active pharmaceutical ingredient (1) | Median price ratio BEQ:referent (2011) (2) | Median price ratio BEQ:referent (2016) (3) | Difference between ratio in 2016 and the ratio in 2011 (4) |
| Group 1 | |||
| Ciclosporin | 85.7% | 66.1% | −19.6% |
| Verapamil | 46.1% | 57.8% | 11.7% |
| Tacrolimus | 81.9% | 66.4% | −15.5% |
| Clomipramine | 49.5% | 45.7% | −3.9% |
| Acenocoumarol | 38.7% | 44.5% | 5.8% |
| Mycophenolate mofetil | 59.3% | 48.7% | −10.6% |
| Zidovudine | BEQ not sold | Referent not sold | |
| Group 2 | |||
| Atorvastatin | 56.1% | 38.0% | −18.0% |
| Cefadroxil | 86.4% | 87.9% | 1.5% |
| Doxycycline | 63.3% | 57.9% | −5.3% |
| Losartan | 47.4% | 43.4% | −4.0% |
| Ketoprofen | 34.9% | 49.6% | 14.7% |
| Levothyroxine | 48.0% | 75.1% | 27.1% |
| Prednisone | 50.4% | Referent not sold | |
| Metformin | 73.0% | 76.2% | 3.3% |
| Clonazepam | 71.2% | 64.9% | −6.3% |
BEQ, bioequivalent.